Cell differentiation in acute myeloid leukemia

European Journal of Haematology

Volumn 57, Issue 1, 1996, Pages 1-16

  Olsson, Inge ^a   Bergh, Gösta ^a   Ehinger, Mats ^a   Gullberg, Urban ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acute myeloid leukemia; Chromosomal translocations; Differentiation; Suppressor genes; Transcription factors

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW CELL; CELL DIFFERENTIATION; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 3; GENE EXPRESSION REGULATION; GENE THERAPY; GROWTH REGULATION; HUMAN; LEUKEMOGENESIS; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0030010877     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1996.tb00483.x     Document Type: Review

References (122)

1. DONG F, HOEFSLOOT LH, SCHELEN AM, et al. Identification of a nonsense mutation in the granulocyte-colony-stimulating factor receptor in severe congenital neutropenia. Proc Natl Acad Sci USA 1994: 91: 4480-4484.
2. BOURETTE RP, MYLES GM, CARLBERG K, CHEN AR, ROHRSCHNEIDER LR. Uncoupling of the proliferation and differentiation signals mediated by the murine macrophage colony-stimulating factor receptor expressed in myeloid FDC-P1 cells. Cell Growth Diff 1995: 6: 631-645.
3. ORKIN SH. Transcription factors and hematopoietic development. J Biol Chem 1995: 270: 4955-4958.
4. HARTWELL LH, KASTAN MB. Cell cycle control and cancer. Science 1994: 266: 1821-1828.
5. HIRAMA T, KOEFFLER P. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995: 86: 841-854.
6. CARROLL M, ZHU Y, D'ANDREA AD. Erythropoietin-induced cellular differentiation requires prolongation of the G1 phase of the cell cycle. Proc Natl Acad Sci USA 1995: 92: 2869-2873.
7. FERRARI S, CALABRETTA B, SELLERI L, et al. Expression of oncogenes and cell cycle related genes in acute and chronic leukemias. Leukemia 1988: 2: 160-166.
8. MIYACHI J, KELLEHER CA, WONG GG, et al. The effects of combination of recombinant growth factors GM-CSF, G-CSF, IL-3 and CSF-1 on leukemic blast cells in suspension culture. Leukemia 1989: 2: 382-387.
9. PEBUSQUE MJ, FAY C, LAFAGE M, et al. Recombinant human IL-3 and G-CSF act synergistically in stimulating growth of acute myeloid leukemia cells. Leukemia 1989: 3: 200-205.
10. RABBITTS TH. Chromosomal translocations in human cancer. Nature 1994: 372: 143-149.
11. RABBITTS TH. Translocations, master genes, and differences between the origins of acute and chronic leukemias. Cell 1991: 67: 641-644.
12. GRIGNANI F, FAGIOLI M, ALCALAY M, et al. Acute promyelocytic leukemia: from genetics to treatment. Blood 1994: 83: 10-25.
13. NUCIFORA G, ROWLEY JD. AMLI and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood 1995: 86: 1-14.
14. LIU PP, HAJRA A, WIJMENGA C, COLLINS FS. Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia. Blood 1995: 85: 2289-2302.
15. BITTER MA, LEBEAU MM, ROWELY JD, et al. Association between morphology, karyotype, and clinical features in myeloid leukemias. Human Pathol 1987: 18: 211-225.
16. ERICKSON P, GAO J, CHANG K-S, et al. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 1992: 80: 1825-1831.
17. MIYOSHI H, KOZU T, SHIMIZU K, et al. The t(8, 21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J 1993: 12: 2715-2721.
18. RUBIN CM, LARSON RA, ANASTASI J, et al. A recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 1990: 76: 2594-2598.
19. NUCIFORA G, BIRN DJ, ESPINOSA III R, et al. Involvement of the AML1 gene in the t(3;21) in therapy-related leukemia and in chonic myeloid leukemia in blast crisis. Blood 1993: 81: 2728-2734.
20. MITANI K, OGAWA S, TANAKA T, et al. Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO J 1994: 13: 504-510.
21. NUCIFORA G, BEGY CR, KOBAYASHI H, et al. Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations. Proc Natl Acad Sci USA 1994: 91: 4004-4008.
22. ROULSTON D, NUCIFORA G, DIETZ-BAND J, LE BEAN MM, ROWLEY JD. Detection of rare 21q22 translocation breakpoints within the AML1 gene in myeloid neoplasms by fluorescense in situ hybridization. Blood 1993: 82(suppl 1): 532a.
23. KAGOSHIMA H, SHIGESADA K, SATAKE M, ITO Y. The runt domain identifies a new family of heteromeric transcriptional regulators. Trends Genet 1993: 9: 338-340.
24. Suzow J, FRIEDMAN AD. The murine myeloperoxidase promoter contains several functional elements, one of which binds a cell type-restricted transcription factor, myeloid nuclear factor 1. (MyNF1). Mol Cell Biol 1993: 13: 2141-2151.
25. NUCHPRAYOON I, MEYERS S, SCOTT LM, et al PEBP2/CBF, the murine homolog of the human myeloid AML1 and PEBP2β/CBFβ proto-oncoproteins, regulates the murine myeloperoxidase and neutrophil elastase genes in immature myeloid cells. Mol Cell Biol 1994: 14: 5558-5568.
26. WANG S, SPECK NA. Purification of core-binding factor, a protein that binds the conserved core site in murine leukemia virus enhancers. Mol Cell Biol 1992: 12: 89-102.
27. TANAKA T, TANAKA K, OGAWA S, et al. An acute myeloid leukemia gene, AML1, regulates hemopoietic myeloid cell differentiation and transcriptional activation antagonistically by two alternative spliced forms. EMBO J 1995: 14: 341-350.
28. MEYERS S, LENNY N, HIBERT SW. The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol Cell Biol 1995: 15: 1974-1982.
29. TSAI S, COLLINS SJ. A dominant negative retinoic acid receptor blocks neutrophil differentiation at the promyelocyte stage. Proc Natl Acad Sci USA 1993: 90: 7153-7157.
30. WARREL JR, RP, DETHÉ H, WANG ZY, DEGOS L. Acute promyelocytic leukemia. N Engl J Med 1993: 329: 177-189.
31. LO COCO F, DIVERIO D, D'ÁDAMO F, et al. PML/RARA rearrangement in acute promyelocytic leukaemias apparently lacking the t(15;17) translocation. Eur J Haematol 1992: 48: 173-176.
32. LAVAU C, DEJEAN A. The t(15;17) translocation in acute promyelocytic leukemia. Leukemia 1994: 8: 1615-1621.
33. GRIGNANI F, FERRUCCI PF, TESTA U, et al. The acute promyelocytic leukemia-specific PML-RARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 1993: 74: 423-431.
34. ROUSSELOT P, HARDAS B, PATEL A, et al. The PML-RARA gene product of the t(15;17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediated transactivation in human myeloid cells. Oncogene 1994: 9: 545-551.
35. LEVIN AA, STURZENBECKER LJ, KAZMER S, et al. 9-cis retinoic acid stereoisomer binds and activates the nuclear receptor RXR alpha. Nature 1992: 355: 359-361.
36. HEYMAN RA, MANGELSDORF DJ, DYCK JA, et al. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 1992: 68: 397-406.
37. PEREZ A, KASTNER P, SETHI S, et al. PMLRAR homodimers: distinct DNA binding properties and heteromeric interactions with RXR. EMBO J 1993: 12: 3171-3182.
38. DELUCA HF. The vitamin D story: a collaborative effort of basic science and clinical medicine. FASEB J 1988: 2: 224-236.
39. Mu Z-M, CHIN K-V, LIU J-H, LOZANO G, CHANG K-S. PML, a growth suppressor disrupted in acute promyelocytic leukemia. Mol Cell Biol 1994: 14: 6858-6867.
40. DYCK JA, MAUL GG, MILLER WH, et al. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 1994: 76: 333-343.
41. WEIS K, RAMBAUD S, LAVAU C, et al. Retinoic acid regulates aberrant nuclear localization of PML-RARα in acute promyelocytic leukemia cells. Cell 1994: 76: 345-356.
42. FIBACH E, LANDAU T, SACHS L. Normal differentiation of myeloid leukemic cells induced by a differentiation-inducing protein. Nature, New Biol. 1972: 237: 276-278.
43. SACHS L. Control of normal cell differentiation and phenotypic reversion of malignancy in myeloid leukemia. Nature 1978: 274: 535-539.
44. SACHS L. The adventures of a biologist: prenatal diagnosis, hematopoiesis, leukemia, carcinogenesis, and tumor suppression. Adv Cancer Res 1995: 66: 1-40.
45. LOTEM J, SACHS L. Regulation by bcl-2, c-myc and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation competent and defective myeloid leukemic cells. Cell Growth Diff 1993: 4: 41-47.
46. GOOTWIN E, WEBB CG, SACHS L. Participation of myeloid of myeloid leukemic cells injected into embryos in hematopoietic differentiation in adult mice. Nature 1982: 299: 63-65.
47. HOZUMI M. Fundamentals of chemo-differentiation therapy of myeloid leukemia. Anticancer Res 1994: 14: 1177-1192.
48. COLLINS SJ, GALLO RC, GALLAGHER RE. Continuous growth and differentiation of human myeloid leukemic cells in suspension culture. Nature 1977: 270: 347-349.
49. SUNDSTRÖM C, NILSSON K. Establishment and characterization of a human histiocytic lymphoma cell-line (U-937). Int J Cancer 1976: 17: 565-577.
50. LOZZIO CB, LOZZIO BB. Human chronic myelogeneous leukemia cell-line with positive Philadelphia chromosome. Blood 1975: 45: 321-334.
51. BREITMAN TR, SELONICK SE, COLLINS SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA 1980: 77: 2936-2940.
52. OLSSON I, SARNGADHARAN MC, BREITMAN TR, GALLO RC. Isolation and characterization of a T-lymphocyte derived differentiation inducing factor (DIF) for myeloid leukemic cells. Blood: 1984: 63: 510-517.
53. PEETRE C, GULLBERG U, NILSSON E, OLSSON I. Effects of recombinant tumor necrosis factor on proliferation and differentiation of leukemic and normal hemopoietic cells in vitro - relationship to cell surface receptor. J Clin Invest 1986: 78: 1694-1700.
54. MIYAURA C, ABE E, KURIBAYASHI T, et al. lalpha,25-dmydroxyvitamin D3 induces differentiation of human myeloid leukemia cells. Biochem Biophys Res Commun 1981: 102: 937-943.
55. OLSSON I, GULLBERG U, IVHED I, NILSSON K. Induction of differentiation of the human histiocytic lymphoma cell line U-937 by 1 alpha,25-dihydroxycholecalciferol. Cancer Res 1983: 53: 5862-5867.
56. BREITMAN TR. Induction of terminal differentiation of HL-60 and fresh leukemic cells by retinoic acid. In: REVOLTELLA RP, PONTIERI GM, BASILICO C, ROVERA G, GALLO RC, SUBAK-SHARPE JH, eds. Expression of Differentiated Functions in Cancer Cells. Raven Press: 1982: 257-273.
57. OLSSON I, BREITMAN TR, GALLO RC. Priming of human myeloid leukemic cell lines (HL-60 and U-937) with retinoic acid for differentiation effects of cyclic AMP-inducing agents and the T-lymphocyte derived differentiation factor. Cancer Res 1982: 42: 3928-3933.
58. DEGOS L, DOMBRET H, CHOMIENNE C, et al. All-trans retinoic acid as differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995: 85: 2643-2653.
59. WEINBERG R. Tumor suppressor genes. Science 1991: 254: 1138-1145.
60. KNUDSON A. Antioncogenes and human cancer. Proc Natl Acad Sci USA 1993: 90: 10914-10921.
61. SRIKUMAR P, CHELLAPAN SP, HIEBERT SP, MUDRYJ M, HOROWITZ JM, NEVTNS JR. The E2F transcription factor is a cellular target for the Rb protein. Cell 1991: 65: 1053-1061.
62. LEES JA, SITO M, VIDAL M, et al. The retinoblastoma protein binds to family of E2F transcription factors. Mol Cell Biol 1993: 13: 7813-7825.
63. WEINBERG RA. The retinoblastoma protein and cell cycle control. Cell 1995: 81: 323-330.
64. FURUKAWA Y, DECAPRIO JA, FREEDMAN A, et al. Expression and the state of phosphorylation of the retinoblastoma susceptibility gene product in cycling and noncycling human hematopoietic cells. Proc Natl Acad Sci USA 1990: 87: 2770-2774.
65. CHEN P-L, SCULLY P, SHEW J-Y, WANG JYJ, LEE W-H. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell 1989: 58: 1193-1198.
66. KIYOKAWA H, RICHON VM, RIFKIND RA, MARKS PA. Suppression of cyclin-dependent kinase 4 during induced differentiation of erythroleukemia cells. Mol Cell Biol 1994: 14: 7195-7203.
67. KATO J-Y, MATSUSHIME H, HIEBERT SW, et al. Direct binding of cyclin D to the retinoblastoma gene product (pRB) and pRB phosphorylation by the cyclin D-dependent kinase, CDK4. Genes Dev 1993: 7: 331-342.
68. KATO J-Y, SHERR CJ. Inhibition of granulocyte differentiation by G1 cyclins D2 and D3 but not D1. Proc Natl Acad Sci USA 1993: 90: 11513-11517.
69. LEE EY-HP, CHANG C-Y, HU N, et al. Mice deficient for RB are nonviable and show defects in neurogenesis and hematopoiesis. Nature 1992: 359: 288-294.
70. CLARKE AR, MAANDAG ER, VANROON M, et al. Requirement for a functional Rb-1 gene in murine development. Nature 1992: 359: 328-330.
71. JACKS T, FAZELI A, SCHMITT EM, et al. Effects of an Rb mutation in the mouse. Nature 1992: 359: 295-300.
72. GU W, SCHNEIDER JW, CONDORELLI G, KAUSHAL S, MAHDAVI V, NADAL-GINARD B. Interaction of myogenic factors and the retinoblastoma protein mediates muscle cell commitment and differentiation. Cell 1993: 72: 309-324.
73. SCHNEIDER JW, GU W, ZHU L, MAHDAVI V, NADAL-GINARD B. Reversal of the terminal differentiaton mediated by p107 in Rb-/- muscle cells. Science 1994: 264: 1467-1471.
74. CONDORELLI GL, TESTA U, VALTIERI M, et al. Modulation of retinoblastoma gene in normal adult hematopoiesis: peak expression and functional role in advanced erythroid differentiation. Proc Natl Acad Sci USA 1995: 92: 4808-4812.
75. WEINTRAUB, SJ, CHOW KNB, LUO RX, ZHANG SH, HE S, DEAN DC. Mechanism of active transcriptional repression by the retinoblastoma protein. Nature 1995: 375: 812-815.
76. PIETENPOL JA, TOKINO T, THIAGALINGAM S, EL-DIERY WS, KINZLER KW, VOGELSTEIN B. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci USA 1994: 91: 1998-2002.
77. DULIC V, KAUFMANN WK, WILSON SJ, et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994: 76: 1013-1023.
78. ZHANG W, GUIYING H, ESTEY E, HESTER J, DEISSEROTH A. Altered conformation of the p53 protein in myeloid leukemia cells and mitogen-stimulated normal blood cells. Oncogene 1992: 7: 1645-1647.
79. LOWE SW, RULEY HE, JACKS T, HOUSMAN DE. p53-dependent apoptosis modulates the cytotoxity of anticancer agents. Cell 1993: 74: 957-967.
80. LOWE SW, BODIS S, MCCLATCHEY A, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994: 266: 807-810.
81. WATTEL E, PREUDHOMME C, HECQUET B, et al. p53 Mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994: 84: 3148-3157.
82. DONEHOWER LA, HARVEY M, SLAGLE BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 1992: 356: 215-221.
83. SHAULSKY G, GOLDFINGER N, PELED A, ROTTER V. Involvement of wild-type p53 in pre-B-cell differentiation. Proc Natl Acad Sci USA 1991: 88: 8982-8986.
84. FEINSTEIN E, GALE RP, REED J, CANAANI E. Expression of normal p53 gene induces differentiation of K-562 cells. Oncogene 1992: 7: 1853-1857.
85. SODDU S, BLANDINO G, CTTRO G, et al. Wild-type p53 gene expression induces granulocytic differentiation of HL-60 cells. Blood 1994: 83: 2230-2237.
86. JOHNSON P, CHUNG S, BENCHIMOL S. Growth suppression of Friend virus-transformed erythroleukemia cells by p53 protein is accompanied by hemoglobin production and is sensitive to erythropoietin. Mol Cell Biol 1993: 13: 1456-1463.
87. HAMEL PA, PHILIPS RA, MUNCASTER M, BRENDA L, GALLIE BL. Speculations on the role of RB in tissue-specific differentiation, tumor initiation, and tumor progression. FASEB J 1993: 7: 846-854.
88. ZHU Y-M, BRADBURY D, RUSSEL N. Decreased retinoblastoma protein expression in acute myeloblastic leukemia is associated with the autonomous proliferation of clonogenic blasts. Br J Haemat 1994: 86: 533-539.
89. KORNBLAU SM, XU H-J, ZHANG W, et al. Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemia. Blood 1994: 84: 256-261.
90. TANG JL, YEH S-H, CHEN P-J, et al. Inactivation of the retinoblastoma gene in acute myelogenous leukaemia. Br J Haematol 1992: 82: 502-507.
91. AHUJA HG, JAT PS, FOTI A, BAR-ELI M, CLINE MJ. Abnormalities of the retinoblastoma gene in the pathogensis of acute leukemia. Blood 1991: 78: 3259-3268.
92. IMAMURA J, MIYOSHI I, KOEFFLER HP. p53 in hematologic malignancies. Blood 1994: 84: 2412-2421.
93. PROKOCIMER M, ROTTER V. Structure and function of p53 in normal cells and their abberations in cancer cells: projection on the hematologic cell lineages. Blood 1994: 84: 2391-2411.
94. KERN SE, PIETENPOL JA, THIAGALINGAM S, SEYMOUR A, KINZLER KW, VOGELSTEIN B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1992: 256: 827-830.
95. MILNER J. A conformation hypothesis for the suppressor and promote functions of p53 in cell growth control and in cancer. Proc R Soc Lond B 1991: 245: 139-145.
96. ULLRICH SJ, MERCER WE, APPELLA E. Human wild-type p53 adopts a unique conformational and phophorylation state in vivo during growth arrest of glioblastoma cells. Oncogene 1992: 7: 1635-1643.
97. BERGH G, EHINGER M, OLSSON I, GULLBERG U. Expression of antisense cDNA for the retinoblastoma tumor suppressor gene inhibits differentiation responses in the monoblastic cell line U-937 (submitted).
98. ZHUO S, FAN S, HUANG S, KAUFMAN S. Study of the role of the retinoblastoma protein in terminal differentiation of murine leukemic cells. Proc Natl Acad Sci 1995: 92: 4234-4238.
99. EHINGER M, NILSSON E, PERSSON A-M, OLSSON I, GULLBERG U. Involvement of tumor suppressor gene p53 in tumor necrosis factor-induced differentiation of the leukemic cell line K-562. Cell Growth Diff 1995: 6: 9-17.
100. EHINGER M, BERGH G, OLOFSSON T, BALDETORP B, OLSSON I, GULLBERG U. Expression of the p53 tumor suppressor gene induces differentiation and promotes induction of differentiation by 1,25-dihydroxycholocalciferol in leukemic U937 cells. Blood 1996: 87: 1064-1074.
101. JIANG H, LIN J, SU Z-Z, et al. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene 1994: 9: 3397-3406.
102. ZHANG W, GRASSO L, MCCLAIN CD, et al. p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/ macrophage differentiation. Cancer Res 1995: 55: 668-674.
103. SHIOHARA M, EL-DEIRY WS, WADA M, et al. Absence of WAF1 mutations in a wide variety of human malignancies. Blood 1994: 84: 3781-3784.
104. HEDRICK L, CHO KR, FEARON ER, WU TC, KINZLER KW, VOGELSTEIN B. The DCC gene product in cellular differentiation and colorectal tumorigenesis. Genes Dev 1994: 8: 1174-1183.
105. MIYAKE K, INOKUCHI K, DAN K, NOMURA T. Alterations in the deleted in colon carcinoma gene in human primary leukemia. Blood 1993: 82: 927-930.
106. HALL A. The cellular functions of small GTP-binding proteins. Science 1990: 249: 635-638.
107. SHANNON KM, WATTERSON J, JOHNSON P, et al. Monosomy 7 myeloproliferative disease in children with neurofibromatosis, type 1: epidemiology and molecular analysis. Blood 1992: 79: 1311-1318.
108. SHANNON KM, O'CONNEL P, MARTIN GA, et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med 1994: 330: 597-601.
109. JACKS T, SHANE SHIH T, SCHMITT EM, BRONSON RT, BERNARDS A, WEINBERG RA. Tumour predisposition in mice heterozygous for a targeted mutation in NF1. Nat Genet 1994: 7: 353-361.
110. SEKIYA M, ADACHI M, HINODA Y, IMAI K, YACHI A. Downregulation of Wilms' tumor gene (wt1) during myelomonocytic differentiation in HL 60 cells. Blood 1994: 83: 1876-1882.
111. PHELAN SA, LINDBERG C, CALL KM. Wilms' tumor gene, WT1, mRNA is down-regulated during induction of erythroid and megakaryocytic differentiation of K562 cells. Cell Growth Diff 1994: 5: 667-686.
112. WU Y-J, FRAIZER GC, SAUNDERS GF. GATA-1 transactivates the WT1 hematopoietic specific enhancer. J Biol Chem 1995: 270: 5944-5949.
113. GOODYER P, DEHBI M, TORBAN E, BRUENING W, PELLETIER J. Repression of the retinoic acid receptor-α gene by the Wilms' tumor suppressor gene product, wt1. Oncogene 1995: 10: 1125-1129.
114. KHARBANDA S, NAKAMURA T, STONE R, et al. Expression of the early growth response 1 and 2 zinc finger genes during induction of monocytic differentiation. J Clin Invest 1991: 88: 571-577.
115. HABER D, SOHN R, BUCKLER A, PELLETIER J, CALL K, HOUSMAN D. Alternative splicing and genomic structure of the Wilms' tumor gene wt-1. Proc Natl Acad Sci USA 1991: 88: 9618-9622.
116. MADDEN SL, COOK DM, MORRIS JF, GASHLER A, SUKHATME VP, RAUSCHER III FJ. Transcriptional repression mediated by the WT-1 Wilms' tumor gene product. Science 1991: 253: 1550-1553.
117. WANG Z-Y, QIU Q-Q M, HUANG J, DUEL TF. WT1, the Wilms' tumor suppressor gene product, represses transcription through an interactive nuclear protein. Oncogene 1995: 10: 1243-1247.
118. REDDY JC, MORRIS JC, WANG J, et al. WT1-mediated transcriptional activation is inhibited by dominant negative mutant proteins. J Biol Chem 1995: 270: 10878-10884.
119. WANG Z-Y, QIU Q-Q, HUANG J, GURRIERI M, DUEL TF. Products of alternatively spliced transcripts of the Wilms' tumor suppressor gene, wt1, have altered DNA binding specificity and regulate transcription in different ways. Oncogene 1995: 10: 415-422.
120. MAHESWARAN S, PARK S, BERNARD A, et al. Physical and functional interaction between WT1 and p53 proteins. Proc Natl Acad Sci USA 1993: 90: 5100-5104.
121. INOUE K, SUGIYAMA H, OGAWA H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994: 84: 3071-3079.
122. BRIEGER J, WEIDMAN E, FENCHEL K, MITROU PS, HOELZER D, BERGMANN L. The expression of the Wilms' tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells. Leukemia 1994: 8: 2138-2143.